MA-INVICRO
23.12.2019 16:04:07 CET | Business Wire | Press release
Invicro LLC, a Konica Minolta company, today announces, Dr. Matthew Silva has been appointed as the new Chief Executive Officer. Dr. Silva will assume the day-to-day leadership responsibilities of the Company and will join Invicro’s Board of Directors, effective immediately. Dr. Jack Hoppin, co-founder of Invicro, will move on from his role as Invicro’s CEO to be the President of Konica Minolta Precision Medicine (KMPM). Dr. Hoppin will remain on Invicro’s Board of Directors, as well as continue to serve on the KMPM Board.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191223005320/en/
Konica Minolta, Inc. acquired Invicro LLC and Ambry Genetics Corporation in September 2017 to accelerate its strategic vision to transform personalized medicine through the delivery of diagnostic services via genetics, imaging and digital pathology capabilities. Konica Minolta Precision Medicine was formalized as a result of bringing these three entities together.
“It has been an extreme honor to serve as Invicro’s CEO, since co-founding the company in 2008,” stated Dr. Hoppin. “This is an exciting time for Invicro, Ambry and KMPM, as we are all working together to support the medical research community through integrated AI technology platforms that allow molecular-level testing and analysis offering insights to advance translational medicine.”
In his new role, Dr. Hoppin will work to synergize the companies under KMPM to help pharmaceutical sponsors and clinicians accelerate the development of targeted therapies through genetic and molecular profiling.
“I’m looking forward to seeing the next chapter for KMPM and Invicro,” said Mr. Kiyotaka Fujii, president of Konica Minolta Global Healthcare and CEO of KMPM. “As KMPM continues to focus on revolutionizing personalized healthcare via the strengths of Konica Minolta, Invicro and Ambry, Jack will be instrumental in leading and realizing the Konica Minolta Precision Medicine mission. I have full confidence that Matt will seamlessly transition to his new role and continue to lead Invicro into new breakthroughs that will help advance the discovery and development of life-changing medicines.”
Dr. Silva will carry on Invicro’s strategic mission to support the drug discovery and development community. Invicro will continue to leverage its industry-leading imaging, chemistry, and analysis expertise that span discovery through clinical research across multiple therapeutic areas, including the central nervous system, oncology, rare disease, and other systemic diseases. Further, Invicro will continue to invest in its data informatics platforms, enabling management, visualization, and analysis of pathological and radiological imaging data and ensuring alignment with KMPM.
“First, I want to thank Jack for leading Invicro to the great success it is today. I’m honored, humbled and extremely excited to assume this new role and carry on the mission,” said Dr. Silva. “It’s an exciting time for Invicro, as we continue to make great strides with our pharma services capabilities offering imaging biomarkers, advanced analytics, innovative chemistry and technologies, and global core lab services. Thanks to Invicro’s dedicated team and our pharma sponsors—we are together helping the development of new medicines that will improve the lives of patients in need.”
With 20 years of diverse imaging experience, Dr. Silva first joined Invicro in 2012 and most recently was EVP of Scientific Applications, where he led strategic efforts to expand the clinical oncology drug development and clinical trials. Dr. Silva’s pharma industry experience includes scientific and leadership positions at Vertex, Amgen, Millennium and Takeda Pharmaceuticals. Dr. Silva holds a Ph.D. and a Master’s degree in Biomedical Engineering from Worcester Polytechnic Institute.
About Invicro
Headquartered in Boston, MA, Invicro was founded in 2008 with the mission of improving the role and function of imaging in translational drug discovery and development across all therapeutic areas. Today, Invicro’s multi-disciplinary team provides solutions to pharmaceutical and biotech companies across all stages of the drug development pipeline (Phase 0-IV), all imaging modalities and all therapeutic areas, including neurology, oncology, and systemic and rare diseases. Invicro’s quantitative biomarker services, advanced analytics and AI tools, and clinical operational services are backed by Invicro’s industry-leading software informatics platforms, VivoQuant® and iPACS®.
As part of the Konica Minolta precision medicine organization and with their sister company Ambry Genetics, Invicro develops and leverages the latest approaches in quantitative biomarkers including imaging, quantitative pathology and genomics. For more information, visit www.invicro.com .
About Konica Minolta Precision Medicine
Konica Minolta Precision Medicine, Inc. (“KMPM”) based in Aliso Viejo, CA is a subsidiary of Konica Minolta, Inc. that includes Ambry Genetics Corporation and Invicro LLC. Founded in 2018 on the belief that groundbreaking medical breakthroughs are possible by concentrating efforts on the health expression map, the undiscovered territory between an individual’s genetics and biological impacts, and quantifiably measuring health over time. KMPM’s health intelligence and visualization platform brings together the most novel and diverse set of data from genes, proteins, cells and tissues with sophisticated analytics and world-leading scientific and medical expertise, enabling more prescriptive, proactive and preventive care. For further information, visit: www.KonicaMinoltaPrecisionMedicine.com
About Konica Minolta
Konica Minolta, Inc. (Konica Minolta) is a global digital technology company with core strengths in imaging and data analysis, optics, materials, and nano-fabrication. Through innovation, Konica Minolta creates products and digital solutions for the betterment of business and society—today and for generations to come. Across its Business Technologies, Healthcare, and Industrial-facing businesses, the company aspires to be an Integral Value Provider that applies the full range of its expertise to offer comprehensive solutions to the customer’s most pressing problems, works with the partners to ensure the solutions are sustainable, anticipates and addresses tomorrow’s issues, and tailors each solution to meet the unique and specific needs of its valued customers. Leveraging these capabilities, Konica Minolta contributes to productivity improvement and workflow change for its customers and provides leading-edge service solutions in the IoT era. Headquartered in Tokyo and with operations in more than 50 countries, Konica Minolta has more than 43,000 employees serving approximately two million customers in over 150 countries. Konica Minolta is listed on the Tokyo Stock Exchange, (TSE4902). For further information, visit: https://www.konicaminolta.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20191223005320/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom